Encephalopathy Associated with Psychotropic Drug Therapy

Odagaki, Yuji

doi:10.5772/29048

Cited by 1 publication

(1 citation statement)

References 162 publications

(173 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of these have been found to cause relatively specific neurological syndromes including diffuse acute or chronic toxic encephalopathy, chronic solvent encephalopathy, cerebellar syndrome, parkinsonism, and vascular encephalopathy [ 45 , 46 ]. There are a number of well-known iatrogenic (pharmaceutical) causes of toxic encephalopathy, for example, some cancer chemotherapeutics [ 97 , 98 ] and psychotherapeutics [ 47 ]. In some cases, including higher treatment doses of mefloquine and other quinolines [ 99 , 100 ], the neuropsychiatric symptoms of the iatrogenic encephalopathy are difficult to distinguish from those of the disease being treated [ 45 , 46 ].…”

Section: Risk-benefit Analysis and Neurotoxicologymentioning

confidence: 99%

Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force

McCarthy¹

2015

Journal of Parasitology Research

View full text Add to dashboard Cite

The Australian Defence Force (ADF) has used mefloquine for malaria chemoprophylaxis since 1990. Mefloquine has been found to be a plausible cause of a chronic central nervous system toxicity syndrome and a confounding factor in the diagnosis of existing neuropsychiatric illnesses prevalent in the ADF such as posttraumatic stress disorder and traumatic brain injury. Overall health risks appear to have been mitigated by restricting the drug's use; however serious risks were realised when significant numbers of ADF personnel were subjected to clinical trials involving the drug. The full extent of the exposure, health impacts for affected individuals, and consequences for ADF health management including mental health are not yet known, but mefloquine may have caused or aggravated neuropsychiatric illness in large numbers of patients who were subsequently misdiagnosed and mistreated or otherwise failed to receive proper care. Findings in relation to chronic mefloquine neurotoxicity were foreseeable, but this eventuality appears not to have been considered during risk-benefit analyses. Thorough analysis by the ADF would have identified this long-term risk as well as other qualitative risk factors. Historical exposure of ADF personnel to mefloquine neurotoxicity now also necessitates ongoing risk monitoring and management in the overall context of broader health policies.

show abstract

Section: Risk-benefit Analysis and Neurotoxicologymentioning

confidence: 99%

Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force

McCarthy¹

2015

Journal of Parasitology Research

View full text Add to dashboard Cite

show abstract

Encephalopathy Associated with Psychotropic Drug Therapy

Cited by 1 publication

References 162 publications

Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force

Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force

Contact Info

Product

Resources

About